.png){kind=logo}
Liran Belenzon is the visionary CEO and co-founder of BenchSci, an AI healthcare company transforming scientific research. Since 2016, he has led the company to global recognition, empowering thousands of scientists and partnering with top pharmaceutical firms. Known for blending innovation with purpose, Liran inspires teams to excel, making science faster, smarter, and life-saving research more impactful worldwide.
Before his entrepreneurial journey, Liran served as an army commander in the Israel Defense Forces, developing leadership and resilience. He earned a law and business degree from Interdisciplinary Center, Israel, then pursued an MBA at the University of Toronto’s Rotman School of Management. There, through the Creative Destruction Lab, he met his future BenchSci co-founders and ignited his startup vision.
Liran’s career began with pioneering startups in Israel, including Biz-Coupon, Israel’s first B2B e-commerce platform, and Standy, an innovative transit advertising venture. In 2016, he co-founded BenchSci, applying AI to accelerate biomedical research. He also contributed as a CDL Associate and Summer Associate at Chinook Capital, honing expertise in venture scaling, acquisitions, and building technology-driven businesses that tackle real-world challenges.
BenchSci uses artificial intelligence to speed up preclinical studies while it solves complex biological problems and improves experimental procedures and scientists' ability to make quick intelligent medical breakthroughs.
AI Partnership: Uses the ASCEND AI platform with Thermo Fisher Scientific to improve experimental design and reagent selection and scientific data analysis which enables scientists to conduct their experiments more efficiently for major scientific breakthroughs.
Decoding Disease: The combination of neuro-symbolic AI and scientific research data enables BenchSci to study disease biology which results in better experimental design methods and faster discovery processes together with precise research findings that advance preclinical studies.
Integrating GenAI: The research process benefits from generative AI tools such as Gemini and NotebookLM which improve workflow efficiency and knowledge organization while they help scientists achieve major life science research breakthroughs.
Trusted AI Assistants: BenchSci creates AI research assistants for pharmaceutical studies which use generative AI together with user-friendly designs and verified scientific facts to increase research speed and trust while making drug development choices more accurate.
AI-Powered: LEAP uses its advanced reasoning system together with knowledge graphs to predict biological results which help scientists design experiments that discover new research connections and create testable research hypotheses and accelerate preclinical research with confidence and accuracy.
AI in Drug Discovery: BenchSci harnesses generative AI to empower scientists to decode disease biology, refine drug design, and speed preclinical research, integrating AI into workflows for faster, smarter, and life-saving discoveries.
Liran has led BenchSci to achieve more than 300 employees while the company raised over $200 million from leading investors who include Google's Gradient Ventures and now serves 15 major pharmaceutical companies which rank among the top 20 in the world. The company uses AI-powered tools to help more than 40,000 scientists around the world while they conduct research and this achievement establishes Liran as a successful entrepreneur who transforms advanced technologies into products that save lives.
Liran Belenzon maintains his current status as a public figure without any significant personal controversies. He leads AI research development for pharmaceutical studies while building BenchSci as an innovative research organization which he leads through his ethical business practices and entrepreneurial vision.
